Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T27670 |
JNJ-26076713
JNJ26076713 |
||
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. |